Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX17 + carboplatin + pemetrexed
- Development stage
- Phase 3
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HLX17 + carboplatin + pemetrexed is a **drug combination** currently in clinical development, typically evaluated for oncology indications such as non-small cell lung cancer. The regimen consists of: - **HLX17**: a biosimilar of pembrolizumab, a monoclonal antibody immune checkpoint inhibitor that targets the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2. This mechanism lifts immune suppression and enhances anti-tumor T-cell activity[1][2][5][6]. - **Carboplatin**: a platinum-based chemotherapeutic agent that forms DNA crosslinks, causing cell cycle arrest and apoptosis in cancer cells. - **Pemetrexed**: an antifolate chemotherapy drug that inhibits key enzymes involved in purine and pyrimidine synthesis, thereby interfering with DNA synthesis and cell replication. This combination leverages both immune checkpoint blockade and cytotoxic chemotherapy, commonly used in advanced lung cancer and other solid tumors.
- Other names
- HLX17 + carboplatin + pemetrexed
02
Targets
DNADHFR (Dihydrofolate reductase)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on HLX17 + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX17 + carboplatin + pemetrexed.